Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
However, published data allows a directional comparison of the most common GI events: Adverse Event Retatrutide (12 mg) Semaglutide 2.4 mg (STEP trials) Tirzepatide 15 mg (SURMOUNT trials) Nausea ~46% ~44% ~31% Diarrhea ~33% ~30% ~23% Vomiting ~22% ~24% ~12% Constipation ~17% ~24% ~12% Important caveat: These numbers come from different trial populations and cannot be directly compared
For instance, if youre experiencing severe nausea or gastrointestinal discomfort, they might lower your dose or switch you to a different GLP-1 medication
Diz-Chaves Y, Herrera-Prez S, Gonzlez-Matas LC, Mallo F
True sustained weight gain affecting more than 5 percent of body weight over 2 to 3 months is less common but documented
GLP-1RAs and dual incretin agonists have been shown to reduce adipocyte hypertrophy and stimulate the activation of BAT, thereby enhancing energy expenditure and metabolic function
US$ 24.78
US$ 25.08
US$ 29.07
US$ 28.27
